A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

The cardiometabolic index was significantly associated with a higher risk for endometriosis, especially at a value exceeding 0.67.

Results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in overweight patients with cardiovascular disease.

The connection between CVD and diabetes cannot be understated, as diabetes impacts CV health and heart conditions affect ...

Patients with sarcoidosis treated with ACE inhibitors had greater mortality risk than those treated with angiotensin receptor blockers.

Low-income patients' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.

TTVR plus optimal medical therapy yields greater improvement in disease-specific and general health status than OMT alone. HealthDay News — For patients with symptomatic and severe or greater ...

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

A study has found that there is a dose-dependent relationship between increased risk for depression and cardiometabolic diseases.

The recent success of drug therapies such as semaglutide and tirzepatide has fueled obesity research. In a phase 2 trial that enrolled patients with type 2 diabetes (ClinicalTrials.gov Identifier: ...